Subjects were randomized 2:1 to receive glasdegib, 100 mg daily, with LDAC 20 mg subcutaneously twice daily on days 1 to 10 of a 28-day cycle (N=77) or LDAC alone (N=38) in 28-day cycles until disease progression or unacceptable toxicity. The trial was conducted in United States, Canada and Europe.Efficacy was established based on an improvement in overall survival (date of randomization to death from any cause). With a median follow-up of 20 months, median survival was 8.3 months (95% CI: 4.4, 12.2) for the glasdegib + LDAC arm and 4.3 months (95% CI: 1.9, 5.7) for the LDAC alone arm and HR of 0.46 (95% CI: 0.30, 0.71; p=0.0002).Glasdegib was granted priority review and orphan drug designation by the U.S. Food and Drug Administration (FDA). It was granted orphan drug designation by the European Medicines Agency (EMA) in October 2017.Glasdegib was approved for medical use in the European Union in June 2020. References
External links
"Glasdegib". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT01546038 for "A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome" at ClinicalTrials.gov
Lopid may refer to:

the Lopit people
the Lopit language
the cholesterol drug gemfibrozil